Senseonics
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 4.9m | 13.7m | 16.4m | 22.4m | 22.2m | 35.8m | 47.5m |
% growth | (77 %) | 176 % | 20 % | 37 % | (1 %) | 61 % | 33 % |
EBITDA | (92.0m) | (57.1m) | (66.9m) | (68.8m) | (73.1m) | (67.0m) | (61.8m) |
% EBITDA margin | (1860 %) | (418 %) | (408 %) | (307 %) | (330 %) | (187 %) | (130 %) |
Profit | (175m) | (302m) | 142m | (60.4m) | (81.0m) | (75.7m) | (82.5m) |
% profit margin | (3539 %) | (2212 %) | 867 % | (270 %) | (365 %) | (212 %) | (174 %) |
EV / revenue | 43.0x | 87.1x | 30.1x | 13.4x | 9.4x | 5.8x | 4.4x |
EV / EBITDA | -2.3x | -20.9x | -7.4x | -4.4x | -2.9x | -3.1x | -3.4x |
R&D budget | 20.4m | 27.2m | 39.7m | 48.8m | - | - | - |
R&D % of revenue | 412 % | 199 % | 242 % | 218 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $15.0m | Debt | |
N/A | $10.0m | Early VC | |
N/A | $10.0m | Early VC | |
N/A | $30.0m | Debt | |
$10.0m | Debt | ||
N/A | $300k | Series D | |
N/A | $10.0m | Series E | |
N/A | $45.0m Valuation: $261m | IPO | |
$41.0m | Post IPO Equity | ||
N/A | $150m | Post IPO Equity | |
* | N/A | $45.0m | Post IPO Debt |
$35.0m | Post IPO Debt | ||
N/A | $50.0m | Post IPO Equity | |
* | $50.0m | Post IPO Debt | |
Total Funding | $30.3m |
Recent News about Senseonics
EditSenseonics is a medical technology company specializing in the development and commercialization of long-term implantable continuous glucose monitoring (CGM) systems. The company's flagship product, the Eversense CGM System, is designed to help individuals with diabetes manage their glucose levels more effectively. This system provides real-time glucose readings, alerts, and data analytics to help patients maintain their target glucose range and reduce hypoglycemia incidents. Senseonics primarily serves patients with diabetes, healthcare providers, and diabetes care specialists. Operating in the medical device market, the company generates revenue through the sale of its CGM systems and related services. The business model focuses on innovation, patient-centric solutions, and partnerships with healthcare providers to enhance diabetes management.
Keywords: implantable CGM, diabetes management, glucose monitoring, Eversense system, medical technology, real-time data, hypoglycemia prevention, healthcare providers, patient-centric, innovation.